CN103070943B - Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine - Google Patents
Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine Download PDFInfo
- Publication number
- CN103070943B CN103070943B CN201310031971.8A CN201310031971A CN103070943B CN 103070943 B CN103070943 B CN 103070943B CN 201310031971 A CN201310031971 A CN 201310031971A CN 103070943 B CN103070943 B CN 103070943B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- traditional chinese
- medicine
- preparation
- fructus crataegi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and a preparation method of the traditional Chinese medicine. The traditional Chinese medicine comprises three raw materials, namely salvia miltiorrhiza, hawthorn and carthamus tinctorius. The traditional Chinese medicine can effectively alleviate myocardium conditions, has significant treatment effects on the cardiovascular and cerebrovascular diseases, particularly on chronic heart diseases, and has the advantages of simple preparation technology, lower cost, pure traditional Chinese medicine preparation, no toxic or side effects, and the like.
Description
Technical field
The invention belongs to field of traditional Chinese medicine formula, be specifically related to a kind of new formula of Chinese medicine for the treatment of cardiovascular and cerebrovascular disease.
Background technology
Cardiovascular and cerebrovascular disease is a series of diseases relating to blood circulation, blood circulation refers to hemophoric Organ and tissue in human body, mainly comprise heart, blood vessel (tremulous pulse, vein, blood capillary), cardiovascular and cerebrovascular disease can be subdivided into acute and chronic cardiovascular and cerebrovascular disease, is all generally relevant with arteriosclerosis.Myocardium cell necrosis after treating myocardial ischemia damage, form cicatrix, thus cause the reconstruct of ventricle, cardiac function goes from bad to worse, and finally causes heart failure, death.And remodeling ventricle mainly judges according to the ejection fraction (EF) of cardiac ultrasonic wave measurement heart, the index such as shortening fraction (FS) and ventricular septum (IVS).About there are 1,700 ten thousand people in the whole world every year because of cardiovascular and cerebrovascular disease death, close to 1/4 of the total death toll of world population.Wherein because acute myocardial infarction and chronic cardiac insufficiency cause dead accounting for more than 50% of cardiovascular and cerebrovascular disease case fatality rate.Therefore the prevention of cardiovascular and cerebrovascular disease has become realistic problem urgently to be resolved hurrily with treatment.
At present, method or the medicine for the treatment of cardiovascular and cerebrovascular disease are in the world varied, as used traditional western medicine, as aspirin, beta-blocker etc.; Surgical therapy, as surgery bypass surgery etc.; Dietotherapy, e.g., patient should on a small quantity eat more, and food should light, being rich in nutrition and easily digest, and notes fluid and electrolyte balance etc.; And treatment by Chinese herbs method, as Traditional Chinese medicinal prescriptions such as Du Shen Tang, five happinesses cardio-cerebral refreshing, BUCHANG NAOXINTONG, SHENGMAI SAN.Though its treatment curative effect is good, but side effect is large and have narrow spectrality, surgical therapy easily leaves postoperative complication to patient, dietotherapy takes effect slowly, though commercially available Chinese medicine preparation curative effect is good, formula is too complicated mostly, and preparation technology is loaded down with trivial details, or because of on the high side, have the problems such as certain universal difficulty etc. shortcoming.But Chinese medicine has had the applicating history of more than one thousand years in treatment atherosclerosis and blood fat reducing, and because of the medicinal property of its uniqueness, as containing Multiple components and targeting multiple protein target spot, therefore the medicine developed based on Chinese medicine formula has reduction side effect, reduce sequela, and the advantage such as instant effect.So the pharmaceutical formulation of exploitation based on Chinese medicine, and simplify formula and preparation method is particularly important.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof, the present invention is a kind of Chinese medicine for the treatment of cardiovascular and cerebrovascular disease of wide spectrum, especially has good curative effect to chronic cardiovascular and cerebrovascular disease.
For achieving the above object, present invention employs following technical scheme:
Treat a Chinese medicine for cardiovascular and cerebrovascular disease, this Chinese medicine is made up of Radix Salviae Miltiorrhizae, Fructus Crataegi and Flos Carthami three kinds of crude drug, described Radix Salviae Miltiorrhizae: Fructus Crataegi: the mass ratio of Flos Carthami is (1-5): (1-5): (1-5).
Described Radix Salviae Miltiorrhizae: Fructus Crataegi: the mass ratio of Flos Carthami is 2:2:1.
Treat a preparation method for the Chinese medicine of cardiovascular and cerebrovascular disease, comprise the following steps: decoct after Radix Salviae Miltiorrhizae, Fructus Crataegi and Flos Carthami mixing with boiling water, then filter to obtain Aqueous extracts, Radix Salviae Miltiorrhizae: Fructus Crataegi: the mass ratio of Flos Carthami is (1-5): (1-5): (1-5).
Described Radix Salviae Miltiorrhizae: Fructus Crataegi: the mass ratio of Flos Carthami is 2:2:1.
The time of described decoction is 0.5-3 hour.
The consumption of described boiling water be Radix Salviae Miltiorrhizae, Fructus Crataegi and Quality of Safflower sum 2-3 doubly.
Radix Salviae Miltiorrhizae is the root of labiate Radix Salviae Miltiorrhizae Salvia miltiorrhiza Bge..Mostly be cultivation, national most area all has.Main product in Sichuan, Anhui, Jiangsu, Henan, the ground such as Shanxi.Spring, season in autumn two excavate, removing impurity and stem and leaf, clean, run through, be cut into sheet, dry., aubergine thick with bar,
There is Flos Chrysanthemi shape white point person for good.
Fructus Crataegi is the dry mature fruit of rosaceous plant Fructus Crataegi Crataegue pinnatifida Bge, Fructus Pyri Pashiae C.pinnatifidaBge.var.Major N.E.Br. and Crataegi cuneatae C.cuneata Sieb.et Zucc..The first two is planted to practise and claims " Fructus Crataegi ", and rear one is practised and claimed " Fructus Crataegi cuneatae ", and Fructus Crataegi dries after cutting into slices, and Fructus Crataegi cuneatae dries after putting in boiling water and slightly scalding, or is pressed into pie and dries.Fructus Crataegi cuneatae with individual all, reddish brown, the meat thick one of color is
Good.
Flos Carthami is the tubular corolla of feverfew Flos Carthami Carthamus tinctorius L., and in all parts of the country have cultivation more, main product in Henan, Hubei, Sichuan, Yunnan, zhejiang and other places.Summer-flowering, plucked when pattern transfers to scarlet by Huang between 5 ~ July, dried in the shade or low baking temperature oven dry.Be good with petal length, color reddish yellow, bright-coloured, the soft person of matter.
Chinese medicine of the present invention compensate for the deficiency of existing medicine or Therapeutic Method, its exploitation is mainly based on following three strategies: first from differential diagnosis in tcm angle, the category that coronary heart disease belongs to " thoracic obstruction ", it is deficient that pathogenesis is mainly the motive, congestion and stagnant the caused blood vessels of expectorant foul smell obstructed, mainly select drug for invigorating blood circulation and eliminating stasis clinically, the Chinese medicine of vital energy regualting and blood circulation-promoting medicine effect carry out symptomatic treatment.The present invention will have the Radix Salviae Miltiorrhizae Flos Carthami of function of promoting blood circulation to disperse blood clots, and have the Fructus Crataegi three compatibility of replenishing QI to invigorate the spleen effect, embody the principle of potentiation combination drug in modern pharmacology; Secondly from system pharmacology angle, in formula of the present invention, three kinds of Chinese medicinal components contain in a large number can compound interactional with cardiovascular disease associated target, and has synergism each other, supports reasonability and the effectiveness of formula of the present invention from molecular level;
The advantages such as last formula of the present invention also has compatibility and preparation process is simple, has no side effect, with low cost, the experiment proved that, the treatment of the present invention to cardiovascular and cerebrovascular disease has significant curative effect, especially morbus cardiacus.
Accompanying drawing explanation
Fig. 1 is ultrasoundcardiogram: (A) sham operated rats, (B) model group, (C) administration group.
Detailed description of the invention
Below in conjunction with drawings and Examples, the invention will be further described.
Embodiment 1: get Radix Salviae Miltiorrhizae 300 grams, be cut into lamellar, then get be cut into lamellar Fructus Crataegi 300 grams, 150 grams, Flos Carthami, decoct 2 hours by after the mixing of three kinds of compositions with 2000 grams of boiling water, after decocting the red Aqueous extracts in leaching filtrate get Dan mountain.Instructions of taking is: 3 times on the one, 300 grams of Aqueous extracts.
Experimental example: set up rat model of myocardial infarction, namely artificial Banded Rats left coronary artery causes Acute myocardial ischemia or infarction, evaluates the impact of the red Aqueous extracts in red mountain on myocardial infarction ischemia or Infarction Model.
Method for establishing model: the male Sprague-Dawley of adult healthy, body weight 199g-226g, be divided into administration group, model group and sham operated rats at random.Wherein administration group is divided into again high, medium and low three dosage.Often organize 10 ~ 15.With the 1% pentobarbital sodium intraperitoneal injection of anesthesia of 50mg/kg after rat weight.For giving
Medicine group and model group, Mus plate is fixed in supine position, left anterior pectorial region preserved skin, chelated iodine sterilization preserved skin
District, through the capable endotracheal intubation of larynx, connects toy respirator, with 80 times/min, the capable artificial respiration of tidal volume 0.7 ~ 0.8mL.In left side, the 3rd rib, the 4th rib place lateral dissection skin, be about 1.5cm, blunt separation
Muscle layer, opens thoracic cavity along the 3rd rib and the 4th intercostal space, expands surgical field of view, tear pericardium with machine for chest-opening,
With sterilized cotton ball hemostasis, under between arterial cone and left auricle, about 1mm place 6/0 toe-in pricks left coronary artery, reset heart subsequently in thoracic cavity, and thoracic wall is sewed up in layering immediately.Postoperative continuous three days injection penicillin prevention infection.Sham operated rats operation process is the same, but only threading not ligation left coronary artery.The postoperative routine of each treated animal is raised.Whether success is with 12 lead electrocardiogram inspections in final modeling.
Administration: administration group with high, normal, basic three dosed administrations, wherein high dose group dosage: middle dosage group dosage: low dose group dosage=4:2:1, low dose group dosage is 3.75g/kg; Once a day, in 24h after modeling, continuous 4 weeks.Model group and sham operated rats give aliquots of deionized water respectively.
Echocardiograph detects: after modeling surrounding, and application VeVo770TM type high-resolution toy ultrasonic image system (being equipped with 20 ~ 45MHz heart excusing from death probe) row Echocardiograph detects.Measure following index aroused in interest, interventricular septum end-systole thickness (IVSd, mm), interventricular septum end-diastolicthickness
(IVSs, mm); LVED (Left Ventricular End Systolic Dimension) (LVIDd, mm), left room end systolic diameter
(LVIDs, mm); LVPW end-diastolicthickness (LVPWd, mm), LVPW end-systole thickness (LVPWs, mm).Average after each excusing from death testing index all gets 3 measured values above.In addition, can reflect the ejection fraction (EF) of ventricular systolic function, Fractional shortening (FS) is calculated by above measured value:
EF=(LVIDd3-LVIDs3)/LVIDd3*100% （1）
FS=(LVIDd-LVIDs)/LVIDd*100% （2）
Experimental result: can find out that the red Aqueous extracts in red mountain of the present invention (Chinese traditional compound medicine) has significantly treatment myocardial infarction effect from the statistical significance of table 1.Ultrasonic experiments show, model group (MI) compared with sham operated rats (Sham), interventricular septum end-systole thickness (IVSd, and interventricular septum end-diastolicthickness (IVSs mm), mm) extremely significantly thinning (P<0.01), LVED (Left Ventricular End Systolic Dimension) (LVIDd
Mm) and end systolic diameter (LVIDs, mm) pole, left room enlarge markedly (P<0.01), penetrate blood system
Number (EF) and shortening fraction (FS) extremely significantly decline, LVPW end-diastolicthickness (LVPWd,
Mm) and LVPW end-systole thickness (LVPWs, mm) unchanged, model group surgeon's knot is described
Fruit reaches the reconfiguration request of the ventricle of expection.Compared with model group, administration group ejection fraction (EF), short
Axle LVFS (FS) and interventricular septum end-systole thickness (IVSd, mm) all have and rise extremely significantly
(P<0.01), in addition, these changes can significantly reflect from this ultrasoundcardiogram of three groups equally
(Fig. 1).Three doses all has certain effect, and wherein high dose effectiveness comparison is remarkable.These results are said
The red Aqueous extracts in Ming Dan mountain can reverse the reconstruct of ventricle, thus effectively prevents recurrence and the heart of myocardial infarction
The cardiovascular and cerebrovascular diseases such as force failure.Therefore, in the process for the treatment of cardiovascular and cerebrovascular disease, use the present invention,
Can effectively alleviate myocardial remodelling situation.The treatment of the present invention to cardiovascular and cerebrovascular disease has significant curative effect.
Table 1 ultrasonic cardiography testing result
| N | Sham | MI | DSH(high dose group) |
| IVSd(mm) | 1.89±0.31 | 1.01±0.11** | 1.46±0.44 |
| IVSs(mm) | 2.81±0.66 | 1.31±0.21** | 2.58±0.39▲▲ |
| LVIDd(mm) | 5.53±0.60 | 9.26±0.76** | 8.49±1.39 |
| LVIDs(mm) | 2.59±0.71 | 7.67±0.61** | 6.31±1.30 |
| LVPWd(mm) | 2.04±0.41 | 1.93±0.41 | 1.96±0.29 |
| LVPWs(mm) | 2.66±0.55 | 2.53±0.46 | 2.62±0.25 |
| EF(%) | 77.97±9.98 | 32.42±8.14** | 60.08±7.89▲▲ |
| FS(%) | 48.93±10.21 | 15.78±4.05** | 39.69±6.01▲▲ |
Compare with sham operated rats: * significant difference; * difference is extremely remarkable
Compare with model group: ▲ significant difference; ▲ ▲ difference is extremely remarkable
Embodiment 2: get Radix Salviae Miltiorrhizae 200 grams, Fructus Crataegi 200 grams, 100 grams, Flos Carthami.Use after three kinds of composition mixing
Pulverizer is ground into Powdered, and then decocts half an hour with 1500 grams of boiling water, crosses the red Aqueous extracts in leaching filtrate get Dan mountain after decocting.
Embodiment 3: get Radix Salviae Miltiorrhizae 100 grams, Fructus Crataegi 200 grams, 500 grams, Flos Carthami.Powdered by being ground into pulverizer after three kinds of composition mixing, and then decoct 1 hour with 2000 grams of boiling water, cross the red Aqueous extracts in leaching filtrate get Dan mountain after decocting.
Embodiment 4: get Radix Salviae Miltiorrhizae 500 grams, Fructus Crataegi 100 grams, 300 grams, Flos Carthami.Powdered by being ground into pulverizer after three kinds of composition mixing, and then decoct half an hour with 2000 grams of boiling water, cross the red Aqueous extracts in leaching filtrate get Dan mountain after decocting.
Embodiment 5: get Radix Salviae Miltiorrhizae 400 grams, Fructus Crataegi 500 grams, 100 grams, Flos Carthami.Powdered by being ground into pulverizer after three kinds of composition mixing, and then decoct 2 hours with 2000 grams of boiling water, cross the red Aqueous extracts in leaching filtrate get Dan mountain after decocting.
Experimental animal model of the present invention is left coronary artery ligation rat.From the data that heart ultrasonic detects, administration group rat is compared with model group rats, cardiac ejection fraction (EF), shortening fraction (FS) and interventricular septum (IVS) all have rising (P<0.01) extremely significantly, illustrate that the red extracting solution in red mountain can reverse the reconstruct of ventricle, thus effectively prevent the cardiovascular and cerebrovascular disease such as recurrence and heart failure of myocardial infarction.Use the present invention can effectively alleviate rat heart muscle situation, the treatment of the present invention to cardiovascular and cerebrovascular disease has significant curative effect, especially morbus cardiacus.It is simple that the present invention has preparation technology, and cost is lower, and pure Chinese medicinal preparation has no side effect.
Claims (5)
1. Chinese medicine is as a purposes for the medicine of preparation treatment myocardial infarction, it is characterized in that: this Chinese medicine is made up of Radix Salviae Miltiorrhizae, Fructus Crataegi and Flos Carthami three kinds of crude drug, described Radix Salviae Miltiorrhizae: Fructus Crataegi: the mass ratio of Flos Carthami is 2:2:1.
2. a kind of Chinese medicine, as the purposes of the medicine of preparation treatment myocardial infarction, is characterized in that: described Chinese medicine can reverse the reconstruct of ventricle, thus effectively prevents recurrence and the heart failure of myocardial infarction according to claim 1.
3. the purposes of the medicine of myocardial infarction treated by a kind of Chinese medicine as preparation according to claim 1, it is characterized in that: the preparation method of described Chinese medicine comprises the following steps: decoct after Radix Salviae Miltiorrhizae, Fructus Crataegi and Flos Carthami mixing with boiling water, then Aqueous extracts is filtered to obtain, Radix Salviae Miltiorrhizae: Fructus Crataegi: the mass ratio of Flos Carthami is 2:2:1.
4. a kind of Chinese medicine, as the purposes of the medicine of preparation treatment myocardial infarction, is characterized in that: the time of described decoction is 0.5-3 hour according to claim 3.
5. a kind of Chinese medicine, as the purposes of medicine of preparation treatment myocardial infarction, is characterized in that according to claim 3: the consumption of described boiling water be Radix Salviae Miltiorrhizae, Fructus Crataegi and Quality of Safflower sum 2-3 doubly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310031971.8A CN103070943B (en) | 2013-01-28 | 2013-01-28 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310031971.8A CN103070943B (en) | 2013-01-28 | 2013-01-28 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103070943A CN103070943A (en) | 2013-05-01 |
| CN103070943B true CN103070943B (en) | 2015-05-13 |
Family
ID=48147789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310031971.8A Expired - Fee Related CN103070943B (en) | 2013-01-28 | 2013-01-28 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103070943B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784624A (en) * | 2014-01-16 | 2014-05-14 | 王秋兰 | Chinese medicine composition for rapidly treating chronic cardiovascular diseases |
| CN105477380A (en) * | 2015-12-16 | 2016-04-13 | 牛鸿祥 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine |
| CN108714188A (en) * | 2018-08-24 | 2018-10-30 | 刘大秀 | A kind of Chinese medicine preparation and preparation method thereof for treating cardiovascular and cerebrovascular |
| CN114306519A (en) * | 2022-01-19 | 2022-04-12 | 项二磊 | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, and its preparation method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857441A (en) * | 2006-03-17 | 2006-11-08 | 崔彬 | Preparation and application of total salvianolic acid composition |
| CN101085071A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root and haw and its preparation |
| CN102233001A (en) * | 2010-05-06 | 2011-11-09 | 菏泽步长制药有限公司 | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases as well as preparation method and detection method thereof |
| CN102793237A (en) * | 2012-08-23 | 2012-11-28 | 山东省农业科学院农产品研究所 | Red sage root-haw beverage and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5692216A (en) * | 1979-12-27 | 1981-07-25 | Sunstar Inc | Peripheral circulation improver containing crude drug |
| JP4628557B2 (en) * | 2001-02-07 | 2011-02-09 | 末人 山上 | Health supplement with action to improve blood circulation disorder |
| JP2008214198A (en) * | 2007-02-28 | 2008-09-18 | Suzuka Univ Of Medical Science | Composition characterized by containing morus plants, lotus plants, crataegus plants, and salvia plants |
| US9597366B2 (en) * | 2010-05-28 | 2017-03-21 | Dong-A University Research Foundation For Industry-Academy Cooperation | Anticancer composition containing herbal extract |
-
2013
- 2013-01-28 CN CN201310031971.8A patent/CN103070943B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857441A (en) * | 2006-03-17 | 2006-11-08 | 崔彬 | Preparation and application of total salvianolic acid composition |
| CN101085071A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root and haw and its preparation |
| CN102233001A (en) * | 2010-05-06 | 2011-11-09 | 菏泽步长制药有限公司 | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases as well as preparation method and detection method thereof |
| CN102793237A (en) * | 2012-08-23 | 2012-11-28 | 山东省农业科学院农产品研究所 | Red sage root-haw beverage and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 慢性病的善后调理;薄廷相;《辽宁中医杂志》;19801231(第12期);第40页，尤其第40页左栏第2段、第3段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103070943A (en) | 2013-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103070943B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine | |
| CN103463409B (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
| CN105412410A (en) | Traditional Chinese medicine preparation for preventing and treating radiographic contrast nephropathy | |
| CN105056192A (en) | Traditional Chinese medicine composition for treating myocardial infarction and application thereof | |
| CN110292607B (en) | Traditional Chinese medicine composition for treating hypertension complicated with left ventricular hypertrophy and preparation method thereof | |
| CN103877411B (en) | A kind of pharmaceutical composition preventing and treating myocardial fibrosis and application thereof | |
| CN104740054B (en) | A kind of pharmaceutical composition for preventing and treating myocardial ischemia and its production and use | |
| CN105727200A (en) | New application of salviae miltiorrhizae and pericarpium trichosanthis formula and medicine composition used for treating chronic pulmonary I type heart disease | |
| CN103372138B (en) | A kind of pharmaceutical composition containing Shengmai Yin active ingredient and preparation method thereof | |
| CN102120000B (en) | Composition of effective parts of traditional Chinese medicine preparation for resisting Coxsackie virus B and preparation method thereof | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN105126034A (en) | Pharmaceutical preparation for treating coronary heart disease | |
| CN103877356B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of myocardial infarction | |
| CN116570702B (en) | Traditional Chinese medicine composition for resisting ejection fraction retention type heart failure and application thereof | |
| CN106728828A (en) | A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease | |
| CN109091532B (en) | Application of Tongguan capsule in preparation of medicine for treating hypertension and heart failure | |
| CN106038997B (en) | Traditional Chinese medicine composition for treating idiopathic pulmonary hypertension and preparation method thereof | |
| CN106668450A (en) | Traditional Chinese medicine preparation for treating sore-toxin and acne | |
| CN104096212A (en) | Traditional Chinese medicine application for treating myocardial infarction and application for same | |
| CN104138556A (en) | Traditional Chinese medicine composition for angina pectoris and preparation method thereof | |
| CN104644886A (en) | Traditional Chinese medicine for treating viral myocarditis and preparation method of traditional Chinese medicine | |
| CN105311425A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating myocardial infarction | |
| CN104940584B (en) | The pharmaceutical composition and its preparation and application and preparation for the treatment of tachyarrhythmia | |
| CN105031286A (en) | Chinese herb preparation for treating iron-deficiency anemia and preparation method thereof | |
| CN105456684A (en) | Traditional Chinese medicine composition for Qi-Yin deficiency type atrial fibrillation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150513 Termination date: 20180128 |